ABVC BioPharma Announces Share Dividend to Reward Shareholders

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, has announced a significant move to distribute shares of its subsidiary, AiBtl BioPharma Inc., as a dividend to its shareholders. This decision, approved by the company's Board of Directors, marks ABVC's first dividend payment, reflecting its confidence in AiBtl's growth potential and its commitment to enhancing shareholder value. Each ABVC shareholder will receive one share of AiBtl for every share of ABVC common stock they own, with an expected distribution of approximately 15 million AiBtl shares.

The distribution is contingent upon the AiBtl shares being included in an effective registration statement under the Securities Act of 1933. AiBtl, in which ABVC holds a 57.8% stake, is focused on developing botanical-based therapeutic candidates for central nervous system disorders, targeting the Asia-Pacific markets. This strategic partnership is anticipated to bolster ABVC's international business development efforts, particularly in the CNS programs for MDD and ADHD markets, and to forge partnerships with global pharmaceutical companies.

Dr. Uttam Patil, ABVC's Chief Executive Officer, expressed pride in the company's progress and its ability to reward shareholders through this dividend distribution. This initiative not only underscores ABVC's belief in AiBtl's long-term prospects but also aims to strengthen shareholder trust in the company's strategic direction and operational capabilities.

This development is noteworthy for investors and the biopharmaceutical industry, as it highlights ABVC's innovative approach to shareholder rewards and its strategic focus on expanding its footprint in the global healthcare market. The move could potentially set a precedent for how biopharmaceutical companies leverage subsidiary growth to deliver value to shareholders and stakeholders alike.